

American National Standard



ANSI/ AAMI/ISO 11135:2014

Sterilization of health care
products —
Ethylene oxide —
Requirements for
development, validation
and routine control of a
sterilization process for
medical devices

Objectives and uses of AAMI standards and recommended practices

It is most important that the objectives and potential uses of an AAMI product standard or recommended practice are clearly understood. The objectives of AAMI's technical development program derive from AAMI's overall mission: the advancement of medical instrumentation. Essential to such advancement are (1) a continued increase in the safe and effective application of current technologies to patient care, and (2) the encouragement of new technologies. It is AAMI's view that standards and recommended practices can contribute significantly to the advancement of medical instrumentation, provided that they are drafted with attention to these objectives and provided that arbitrary and restrictive uses are avoided.

A voluntary *standard* for a *medical device* recommends to the manufacturer the information that should be provided with or on the product, basic safety and performance criteria that should be considered in qualifying the device for clinical use, and the measurement techniques that can be used to determine whether the device conforms with the safety and performance criteria and/or to compare the performance characteristics of different products. Some standards emphasize the information that should be provided with the device, including performance characteristics, instructions for use, warnings and precautions, and other data considered important in ensuring the safe and effective use of the device in the clinical environment. Recommending the disclosure of performance characteristics often necessitates the development of specialized test methods to facilitate uniformity in reporting; reaching consensus on these tests can represent a considerable part of committee work. When a drafting committee determines that clinical concerns warrant the establishment of *minimum* safety and performance criteria, referee tests must be provided and the reasons for establishing the criteria must be documented in the rationale.

A *recommended practice* provides guidelines for the use, care, and/or processing of a medical device or system. A recommended practice does not address device performance *per se*, but rather procedures and practices that will help ensure that a device is used safely and effectively and that its performance will be maintained.

Although a device standard is primarily directed to the manufacturer, it may also be of value to the potential purchaser or user of the device as a frame of reference for device evaluation. Similarly, even though a recommended practice is usually oriented towards healthcare professionals, it may be useful to the manufacturer in better understanding the environment in which a medical device will be used. Also, some recommended practices, while not addressing device performance criteria, provide guidelines to industrial personnel on such subjects as sterilization processing, methods of collecting data to establish safety and efficacy, human engineering, and other processing or evaluation techniques; such guidelines may be useful to health care professionals in understanding industrial practices.

In determining whether an AAMI standard or recommended practice is relevant to the specific needs of a potential user of the document, several important concepts must be recognized:

All AAMI standards and recommended practices are *voluntary* (unless, of course, they are adopted by government regulatory or procurement authorities). The application of a standard or recommended practice is solely within the discretion and professional judgment of the user of the document.

Each AAMI standard or recommended practice reflects the collective expertise of a committee of health care professionals and industrial representatives, whose work has been reviewed nationally (and sometimes internationally). As such, the consensus recommendations embodied in a standard or recommended practice are intended to respond to clinical needs and, ultimately, to help ensure patient safety. A standard or recommended practice is limited, however, in the sense that it responds generally to perceived risks and conditions that may not always be relevant to specific situations. A standard or recommended practice is an important *reference* in responsible decision-making, but it should never *replace* responsible decision-making.

Despite periodic review and revision (at least once every five years), a standard or recommended practice is necessarily a static document applied to a dynamic technology. Therefore, a standards user must carefully review the reasons why the document was initially developed and the specific rationale for each of its provisions. This review will reveal whether the document remains relevant to the specific needs of the user.

Particular care should be taken in applying a product standard to existing devices and equipment, and in applying a recommended practice to current procedures and practices. While observed or potential risks with existing equipment typically form the basis for the safety and performance criteria defined in a standard, professional judgment must be used in applying these criteria to existing equipment. No single source of information will serve to identify a particular product as "unsafe". A voluntary standard can be used as one resource, but the ultimate decision as to product safety and efficacy must take into account the specifics of its utilization and, of course, cost-benefit considerations. Similarly, a recommended practice should be analyzed in the context of the specific needs and resources of the individual institution or firm. Again, the rationale accompanying each AAMI standard and recommended practice is an excellent guide to the reasoning and data underlying its provision.

In summary, a standard or recommended practice is truly useful only when it is used in conjunction with other sources of information and policy guidance and in the context of professional experience and judgment.

INTERPRETATIONS OF AAMI STANDARDS AND RECOMMENDED PRACTICES

Requests for interpretations of AAMI standards and recommended practices must be made in writing, to the AAMI Vice President, Standards Policy and Programs. An official interpretation must be approved by letter ballot of the originating committee and subsequently reviewed and approved by the AAMI Standards Board. The interpretation will become official and representation of the Association only upon exhaustion of any appeals and upon publication of notice of interpretation in the "Standards Monitor" section of the *AAMI News*. The Association for the Advancement of Medical Instrumentation disclaims responsibility for any characterization or explanation of a standard or recommended practice which has not been developed and communicated in accordance with this procedure and which is not published, by appropriate notice, as an *official interpretation* in the *AAMI News*.

American National Standard

ANSI/AAMI/ISO 11135:2014
(Combined revision of ANSI/AAMI/ISO 11135-1:2007
and ANSI/AAMI/ISO TIR11135-2:2007)

Sterilization of health care products — Ethylene oxide — Requirements for development, validation and routine control of a sterilization process for medical devices

Approved 30 March 2015 by
Association for the Advancement of Medical Instrumentation

Approved 27 July 2015 by
American National Standards Institute

Abstract: Specifies requirements for the development, validation, and routine control of an ethylene oxide sterilization process for medical devices.

Keywords: EO, industrial sterilization, validation, routine control, medical device, product release, process control, process monitoring

This is a preview. [Click here to purchase the full publication.](#)

AAMI Standard

This Association for the Advancement of Medical Instrumentation (AAMI) standard implies a consensus of those substantially concerned with its scope and provisions. The existence of an AAMI standard does not in any respect preclude anyone, whether they have approved the standard or not, from manufacturing, marketing, purchasing, or using products, processes, or procedures not conforming to the standard. AAMI standards are subject to periodic review, and users are cautioned to obtain the latest editions.

CAUTION NOTICE: This AAMI standard may be revised or withdrawn at any time. AAMI procedures require that action be taken to reaffirm, revise, or withdraw this standard no later than five years from the date of publication. Interested parties may obtain current information on all AAMI standards by calling or writing AAMI.

All AAMI standards, recommended practices, technical information reports, and other types of technical documents developed by AAMI are *voluntary*, and their application is solely within the discretion and professional judgment of the user of the document. Occasionally, voluntary technical documents are adopted by government regulatory agencies or procurement authorities, in which case the adopting agency is responsible for enforcement of its rules and regulations.

Published by

Association for the Advancement of Medical Instrumentation
4301 North Fairfax Drive, Suite 301
Arlington, VA 22203

© 2015 by the Association for the Advancement of Medical Instrumentation

All Rights Reserved

This publication is subject to copyright claims of ISO, ANSI, and AAMI. No part of this publication may be reproduced or distributed in any form, including an electronic retrieval system, without the prior written permission of AAMI. All requests pertaining to this document should be submitted to AAMI. It is illegal under federal law (17 U.S.C. § 101, *et seq.*) to make copies of all or any part of this document (whether internally or externally) without the prior written permission of the Association for the Advancement of Medical Instrumentation. Violators risk legal action, including civil and criminal penalties, and damages of \$100,000 per offense. For permission regarding the use of all or any part of this document, contact AAMI, 4301 North Fairfax Drive, Suite 301, Arlington, VA 22203. Phone: (703) 525-4890; Fax: (703) 276-0793.

Printed in the United States of America

ISBN 1-57020-596-5

This is a preview. [Click here to purchase the full publication.](#)

Contents

Page

Glossary of equivalent standards	vi
Committee representation	vii
Background of AAMI adoption of ISO 11135-1:2007	x
Foreword	xi
Introduction	xii
1 Scope.....	1
1.1 Inclusions.....	1
1.2 Exclusions	1
2 Normative references.....	2
3 Terms and definitions.....	3
4 Quality management systems	11
4.1 Documentation.....	11
4.2 Management responsibility	11
4.3 Product realization.....	11
4.4 Measurement, analysis and improvement — Control of nonconforming product.....	11
5 Sterilizing agent characterization	12
5.1 General.....	12
5.2 Sterilizing agent	12
5.3 Microbicidal effectiveness.....	12
5.4 Material effects	12
5.5 Safety and the environment.....	12
6 Process and equipment characterization	12
6.1 General.....	12
6.2 Process characterization	13
6.3 Equipment characterization	14
7 Product definition	15
7.1 General.....	15
7.2 Product safety, quality and performance	15
7.3 Microbiological quality.....	15
7.4 Documentation.....	16
8 Process definition	16
9 Validation	17
9.1 General.....	17
9.2 Installation qualification, IQ.....	17
9.2.1 Equipment	17
9.2.2 Installation qualification	17
9.3 Operational qualification, OQ.....	18
9.4 Performance qualification, PQ	18
9.4.1 General.....	18
9.4.2 Performance qualification — Microbiological	19
9.4.3 Performance qualification — Physical	19
9.5 Review and approval of validation	20
10 Routine monitoring and control	22
11 Product release from sterilization.....	24

12	Maintaining process effectiveness	24
12.1	General	24
12.2	Maintenance of equipment	24
12.3	Requalification	25
12.4	Assessment of change	25
12.5	Assessment of equivalence	25
12.5.1	Process Equivalence	25
12.5.2	Product	26
Annex A (normative)	Determination of lethal rate of the sterilization process — Biological indicator/bioburden approach	27
A.1	General	27
A.2	Procedure	27
Annex B (normative)	Conservative determination of lethal rate of the sterilization process — Overkill approach	28
B.1	General	28
B.2	Procedure	28
Annex C (informative)	Temperature sensors, RH sensors and biological indicator numbers	30
C.1	Temperature sensors	30
C.2	Humidity sensors	31
C.3	Biological Indicators	31
Annex D (informative)	Guidance on the application of the normative requirements	33
D.1	Scope	33
D.2	Normative references	33
D.3	Terms and definitions	33
D.4	Quality management systems	33
D.4.1	Documentation	33
D.4.2	Management responsibility	33
D.4.3	Product realization	34
D.4.4	Measurement, analysis and improvement — Control of non-conforming product	34
D.5	Sterilizing agent characterization	34
D.5.1	General	34
D.5.2	Sterilizing agent	35
D.5.3	Microbicidal effectiveness	35
D.5.4	Material effects	35
D.5.5	Safety and the environment	35
D.6	Process and equipment characterization	36
D.6.1	General	36
D.6.2	Process characterization	36
D.6.3	Equipment characterization	38
D.7	Product definition	40
D.7.1	General	40
D.7.2	Product safety, quality and performance	43
D.7.3	Microbiological quality	45
D.7.4	Documentation	45
D.8	Process definition	45
D.9	Validation	49
D.9.1	General	49

D.9.2	Installation qualification	49
D.9.2.1	Equipment	49
D.9.2.2	Installation qualification	50
D.9.3	Operational qualification	51
D.9.4	Performance qualification	53
D.9.4.1	General.....	53
D.9.4.2	Performance qualification — Microbiological.....	54
D.9.4.3	Performance qualification — Physical	55
D.9.4.4	Review and approval of validation	56
D.10	Routine monitoring and control.....	57
D.11	Product release from sterilization.....	60
D.12	Maintaining process effectiveness.....	60
D.12.1	General.....	60
D.12.2	Maintenance of equipment	61
D.12.3	Requalification	62
D.12.4	Assessment of change	64
D.12.5	Assessment of equivalence	65
D.12.5.1	Process equivalence	65
D.12.5.2	Criteria for process equivalence	65
D.12.5.3	Determination of process equivalence	66
D.12.5.4	Process analysis and evaluation	66
D.12.5.5	Evaluation of preconditioning or aeration areas	66
D.12.5.6	Evaluation of sterilization chamber performance.....	66
D.12.5.7	Microbiological evaluation	67
D.12.5.8	Results evaluation.....	67
D.12.5.9	Maintenance of equivalence.....	68
D.12.5.10	Documentation	68
D.12.5.11	Product.....	68
D.12.5.11.1	Product family	68
D.12.5.11.2	Determination of adverse effects to product.....	69
D.12.5.11.3	Determination of product design effects.....	69
D.12.5.11.4	Determination of product material and characteristics effects.....	70
D.12.5.11.5	Determination of sterile barrier system effects	70
D.12.5.11.6	Determination of load configuration effects	70
D.12.5.11.7	Conclusions of product adoption evaluation.....	70
D.13	Guidance on Annex A — Determination of lethal rate of the sterilization process — Biological indicator/bioburden approach	70
D.13.1	[A.1] General	70
D.13.2	[A.2] Procedure.....	72
D.14	Guidance on Annex B — Conservative determination of lethal rate of the sterilization process — Overkill approach.....	73
D.14.1	[B.1] General	73
D.14.2	[B.2] Procedure.....	74
Annex E (normative)	Single Lot Release	75
E.1	General.....	75
E.2	Procedure	75
Bibliography	77

Glossary of equivalent standards

International Standards adopted in the United States may include normative references to other International Standards. AAMI maintains a current list of each International Standard that has been adopted by AAMI (and ANSI). Available on the AAMI website at the address below, this list gives the corresponding U.S. designation and level of equivalency to the International Standard.

www.aami.org/standards/glossary.pdf

Committee representation

Association for the Advancement of Medical Instrumentation Ethylene Oxide Sterilization Working Group

The adoption of ISO 11135:2014 as an AAMI standard was initiated by the Ethylene Oxide Sterilization Working Group of the AAMI Sterilization Standards Committee (AAMI/ST), which also functions as a U.S. Technical Advisory Group to the relevant work in the International Organization for Standardization (ISO). U.S. representatives from the AAMI Ethylene Oxide Sterilization Working Group (U.S. Sub-TAG for ISO/TC 198/WG 1), chaired by Jeff Martin and Gerry O'Dell, played an active part in developing the ISO Standard.

Committee approval of this document does not necessarily imply that all committee members voted for its approval.

At the time this document was published, the **AAMI Ethylene Oxide Sterilization Working Group** had the following members:

Cochairs Jeff Martin
 Gerry O'Dell

Members Erin Armstrong, B Braun of America Inc
 Ed Arscott, NAMSA
 Anne Booth, Booth Scientific Inc
 Lloyd Brown, Covidien
 Tim Carlson, Becton Dickinson & Company
 Sarah Chamberlain, Accuratus Labs Services
 Denny Christensen, Mesa Laboratories Biological Indicator Division- Bozeman Facility
 Gary Cranston, Consulting & Technical Services/PCS
 Elaine Daniell, CR Bard
 Douglas Davie, Sterilization Validation Services
 Darci Diage, Direct Flow Medical Inc
 Mary Ann Drosnock, Healthmark Industries Company Inc
 Paul Fioriti, Company for Individuals
 William FitzGerald, FitzGerald & Associates Ltd
 Dan Floyd, Nelson Laboratories Inc
 Lisa Foster, Aduvo QS & SA Consulting
 Zory Glaser, Johns Hopkins University-School of Public Health
 Mike Groendyk, Javelin Medical
 Doug Harbrecht, Sterility Assurance LLC
 Arthur Harris, Cook Inc
 Deborah Havlik, Hospira Worldwide Inc
 Jason Hedrick, Medtronic Inc WHQ Campus
 Krista Howard, WL Gore & Associates Inc
 Danny Hutson, CareFusion
 Nupur Jain, Intuitive Surgical Inc
 Carolyn Kinsley, LexaMed Ltd
 Karen Kowalczyk, Centurion Sterilization Services
 Christine Loshbaugh, Edwards LifeSciences
 Jeff Martin, Alcon Laboratories Inc
 Ted May, Andersen Products Inc
 Patrick McCormick, Bausch & Lomb Inc
 David McGoldrick, Abbott Laboratories
 Rusty Mills, GE Healthcare
 Gary Mitchel, Johnson & Johnson
 Sarah Mowitt, Mowitt, Sarah - 322573
 Gerry O'Dell, Gerry O'Dell Consulting
 Dave Parente, Ecolab
 Michelle Peterson, Stryker Instruments Division
 Nancy Rakiewicz, IUVO BioScience
 Beth Ridgeway, Mesa Laboratories Biological Indicator Division- Bozeman Facility
 Manny Saavedra, Halyard Health
 Jon Seulean, Terumo BCT

Mark Seybold, Baxter Healthcare Corporation
 Harry Shaffer, Sterilization Consulting Services
 David Silor, Zimmer Inc
 Bill South, Steris Corporation
 Michael Sprague, Ethide Laboratories Inc
 Sopheak Srun, Quality Tech Services Inc
 Ralph Stick, WuXi AppTec Inc
 Fenil Sutaria, Medline Industries Inc
 Radhakrishna Tirumalai, US Pharmacopeia Convention Inc
 Steven Turtill, FDA/CDRH
 Craig Wallace, 3M Healthcare
 Richard Warburton, Company for Individuals
 Bud Weisman, Fresenius Medical Care
 Beverly Whitaker, Indigo Consulting Group LLC
 Stacy Wiehle, Boston Scientific Corporation
 Dennis Wildes, St Jude Medical Inc
 Bill Young, Sterigenics International

Alternates

August Baur, Centurion Sterilization Services
 MarJean Boyter, Fresenius Medical Care
 Robert Bradley, Mesa Laboratories Biological Indicator Division- Bozeman Facility
 Carolyn Braithwaite-Nelson, Spectranetics Corporation
 Trabue Bryans, BryKor LLC
 Susan Bullis, Johnson & Johnson
 Greg Bush, Alcon Laboratories Inc
 Claudia Camp, Stryker Instruments Division
 Greg Crego, IUVO BioScience
 Jeffrey Delgaudio, Covidien
 Jessica Desmond, Accuratus Labs Services
 John DiCaro, Covidien
 Dave Dion, Cardinal Health (MP&S)
 David Dominguez, CareFusion
 Brian Drumheller, CR Bard
 Steven Elliott, FDA/CDRH
 Diane Faivre-Swiat, Cardinal Health (MP&S)
 Naomi Gamm, St Jude Medical Inc
 Scott Giraud, Medtronic Inc WHQ Campus
 Ken Gordon, Steris Corporation
 David Hilliker, ChemDAQ Inc
 Nichole Jackson, Ecolab
 Chris Kobus, GE Healthcare
 Ezra Koski, Terumo BCT
 Jim Kulla, LexaMed Ltd
 Wesley Lantz, Zimmer Inc
 John Lindley, Andersen Products Inc
 Paul Littley, Nelson Laboratories Inc
 Ronald Lulich, 3M Healthcare
 Joseph Mello, Ethide Laboratories Inc
 Laurie Nawrocki, NAMSA
 Susumu Nozawa, Becton Dickinson & Company
 Koyejo Obadina, Abbott Laboratories
 Mike Padilla, Sterigenics International
 Andrew Porteous, Baxter Healthcare Corporation
 Tyrone Rouse, Halyard Health
 Matthew Russell, Cook Inc
 Arnie Shechtman, Medline Industries Inc
 Jade Schiesser, Quality Tech Services Inc
 Mike Schoene, Bausch & Lomb Inc
 Brian Wallace, Intuitive Surgical Inc
 Daryl Woodman, Andersen Products Inc
 Bryan Worwa, Boston Scientific Corporation
 Cas Woss, FitzGerald & Associates Ltd

AAMI Sterilization Standards Committee

<i>Cochairs</i>	Victoria M. Hitchins, PhD, FDA/CDRH William E. Young, Boston Scientific Corporation
<i>Members</i>	Trabue D. Bryans, AppTec Nancy Chobin, RN CSPDM, St Barnabas Healthcare System Charles Cogdill, Boston Scientific Corporation Ramona Conner, RN MSN CNOR, Association of Perioperative Registered Nurses Jacqueline Daley, Association for Professionals in Infection Control and Epidemiology Kimbrell Darnell, CR Bard Lisa Foster, Sterigenics International James M. Gibson, Jr., JM Gibson Associates Joel R. Gorski, PhD, NAMSA Deborah A. Havlik, Hospira Inc Victoria M. Hitchins, PhD, FDA/CDRH Danny Hutson, Cardinal Health (MP&S) Lois Atkinson Jones, MS, (Independent Expert) Susan G. Klacik, AS BS, IAHCSMM Byron J. Lambert, PhD, Abbott Laboratories Colleen Patricia Landers, RN, Canadian Standards Association David Liu, Johnson & Johnson Jeff Martin, Alcon Laboratories Inc Patrick J. McCormick, PhD, Bausch & Lomb Inc Susie McDonald, American Society for Healthcare Central Service Professionals Thomas K. Moore, Getinge USA Barry F.J. Page, Cook Endoscopy Nancy J. Rakiewicz, Ethox International Inc Phil M. Schneider, 3M Healthcare Michael H. Scholla, Dupont Nonwovens Mark Seybold, Baxter Healthcare Corporation Andrew Sharavara, Propper Manufacturing Co Inc William N. Thompson, TYCO Healthcare John W. Walker, STERIS Corporation James L. Whitby, MA, MB, FRCP, University of Western Ontario Thelma Wilcott, Becton Dickinson & Company Martell Kress Winters, BS SM, Nelson Laboratories Inc
<i>Alternates</i>	Lloyd Brown, TYCO Healthcare Lina C. Bueno, Dupont Nonwovens Dave Dion, Cardinal Health (MP&S) Thomas J. Frazar, Johnson & Johnson Kathy Hoffman, Sterigenics International Clark W. Houghtling, STERIS Corporation Jim Kaiser, Bausch & Lomb Inc Joseph J. Lasich, BS, Alcon Laboratories Inc Chiu S. Lin, PhD, FDA/CDRH Natalie Lind, IAHCSMM Lisa N. Macdonald, Becton Dickinson & Company Ralph Makinen, Boston Scientific Corporation Mary S. Mayo, CR Bard David Ford McGoldrick, BS, Abbott Laboratories Jerry R. Nelson, MS PhD, Nelson Laboratories Inc Janet M. Prust, 3M Healthcare Mike Sadowski, Baxter Healthcare Corporation Ralph Stick, AppTec Jason Voisinnet, Ethox International Inc Valerie Welter, Hospira Inc William E. Young, Boston Scientific Corporation

NOTE—Participation by federal agency representatives in the development of this standard does not constitute endorsement by the federal government or any of its agencies.
